DBV Technologies S.A. (NASDAQ:DBVT) Receives $38.65 Consensus Target Price from Brokerages

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have been assigned an average rating of “Moderate Buy” from the nine research firms that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, four have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $38.65.

Several equities research analysts have recently commented on DBVT shares. Guggenheim reissued a “buy” rating and set a $51.00 target price on shares of DBV Technologies in a research report on Friday, March 27th. Citizens Jmp boosted their target price on shares of DBV Technologies from $45.00 to $47.00 and gave the stock a “market outperform” rating in a research report on Friday, March 27th. Finally, Wall Street Zen downgraded shares of DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th.

Institutional Investors Weigh In On DBV Technologies

Hedge funds and other institutional investors have recently made changes to their positions in the business. Allworth Financial LP bought a new stake in shares of DBV Technologies during the fourth quarter worth about $32,000. Royal Bank of Canada bought a new stake in DBV Technologies in the 4th quarter worth about $34,000. GAMMA Investing LLC grew its position in DBV Technologies by 38.4% in the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock worth $51,000 after purchasing an additional 744 shares in the last quarter. New York State Common Retirement Fund bought a new stake in DBV Technologies in the 3rd quarter worth about $34,000. Finally, Truvestments Capital LLC grew its position in DBV Technologies by 71.3% in the 4th quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock worth $75,000 after purchasing an additional 1,620 shares in the last quarter. 71.74% of the stock is owned by institutional investors.

DBV Technologies Price Performance

NASDAQ:DBVT opened at $20.30 on Thursday. The firm has a 50-day moving average of $20.89 and a 200-day moving average of $18.84. The company has a market cap of $1.13 billion, a PE ratio of -3.89 and a beta of -0.94. DBV Technologies has a one year low of $7.53 and a one year high of $26.18.

DBV Technologies (NASDAQ:DBVT) last posted its earnings results on Saturday, February 14th. The company reported ($1.15) EPS for the quarter. The business had revenue of $0.65 million for the quarter. DBV Technologies had a negative return on equity of 189.17% and a negative net margin of 2,606.83%. On average, equities research analysts expect that DBV Technologies will post -0.82 earnings per share for the current fiscal year.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.